Targeted drug trial seeks to control Tough-to-Treat cancers
NCT ID NCT04520269
Summary
This study is testing if the drug pacritinib can help control the growth of advanced solid tumors that have a specific genetic feature called 1q21.3 amplification. It is enrolling up to 74 adults with cancers, mostly breast cancer, that have stopped responding to standard treatments. The goal is to see if the drug is safe and if it can stop the cancer from getting worse for at least 4 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore
Conditions
Explore the condition pages connected to this study.